Effect of N-Acetylcysteine on Residual Renal Function in Chronic Hemodialysis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00507052|
Recruitment Status : Unknown
Verified July 2007 by Assaf-Harofeh Medical Center.
Recruitment status was: Not yet recruiting
First Posted : July 25, 2007
Last Update Posted : July 25, 2007
In our opinion, it is worth to check an ability of antioxidant therapy to produce a favorable effect on Residual Renal Function.
The aim of our study is to investigate the effect of N-acetylsysteine on RRF in prevalent HD patients.
|Condition or disease||Intervention/treatment||Phase|
|Hemodialysis Renal Failure||Drug: N-acetylcysteine||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00507052
|Contact: Leonid S Feldman, MD||+972-8-9779383 ext +firstname.lastname@example.org|
|Assaf Harofeh||Not yet recruiting|
|Zerifin, Israel, 70300|
|Contact: Leonid S Feldman, MD +972-8-9779383 ext +972 email@example.com|
|Principal Investigator:||Leonid S Feldman, MD||Assaf Harofeh MC|